Healthcare provider profile · identity verified

Gary Matthew Cox, M.D.

Infectious Disease · DURHAM, NC · NPI 1396808168

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	296	34
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	292	31
Tivicay	Dolutegravir Sodium	234	24
Gabapentin	Gabapentin	202	32
Atorvastatin Calcium	Atorvastatin Calcium	176	34
Prezcobix	Darunavir/Cobicistat	169	17
Triumeq	Abacavir/Dolutegravir/Lamivudi	162	16
Amlodipine Besylate	Amlodipine Besylate	159	28
Ritonavir	Ritonavir	152	17
Descovy	Emtricitabine/Tenofov Alafenam	122	11
Rosuvastatin Calcium	Rosuvastatin Calcium	119	18
Darunavir	Darunavir	117	14
Omeprazole	Omeprazole	105	19
Losartan Potassium	Losartan Potassium	103	16
Trazodone Hcl	Trazodone Hcl	100	15
Valacyclovir	Valacyclovir Hcl	100	15
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	95	suppressed
Oxycodone Hcl	Oxycodone Hcl	89	11
Isentress	Raltegravir Potassium	88	suppressed
Diazepam	Diazepam	86	11
Efavirenz-Emtric-Tenofov Disop	Efavirenz/Emtricit/Tenofovr Df	86	suppressed
Valsartan	Valsartan	85	17
Lisinopril	Lisinopril	84	16
Albuterol Sulfate Hfa	Albuterol Sulfate	83	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	81	12
Hydrochlorothiazide	Hydrochlorothiazide	76	12
Lorazepam	Lorazepam	76	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	68	suppressed
Dovato	Dolutegravir Sodium/Lamivudine	65	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	65	22
Odefsey	Emtricitab/Rilpiviri/Tenof Ala	65	suppressed
Duloxetine Hcl	Duloxetine Hcl	64	suppressed
Ibuprofen	Ibuprofen	61	11
Etravirine	Etravirine	58	suppressed
Jardiance	Empagliflozin	56	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	54	suppressed
Alprazolam	Alprazolam	53	suppressed
Metformin Hcl	Metformin Hcl	52	suppressed
Vancomycin Hcl	Vancomycin Hcl	49	suppressed
Benazepril Hcl	Benazepril Hcl	44	suppressed
Dronabinol	Dronabinol	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Fluconazole	Fluconazole	38	13
Tramadol Hcl	Tramadol Hcl	38	suppressed
Ondansetron Hcl	Ondansetron Hcl	37	suppressed
Promethazine Hcl	Promethazine Hcl	37	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	36	suppressed
Emtricitabine-Tenofovir Disop	Emtricitabine/Tenofovir (Tdf)	35	suppressed
Prezista	Darunavir	35	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	33	suppressed
Acyclovir	Acyclovir	31	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	31	suppressed
Carvedilol	Carvedilol	30	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Symtuza	Darunavir/Cob/Emtri/Tenof Alaf	29	suppressed
Efavirenz	Efavirenz	28	suppressed
Finasteride	Finasteride	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Amoxicillin	Amoxicillin	27	suppressed
Atenolol	Atenolol	27	suppressed
Edurant	Rilpivirine Hcl	27	suppressed
Gemfibrozil	Gemfibrozil	26	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	25	suppressed
Pregabalin	Pregabalin	25	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	25	suppressed
Terbinafine Hcl	Terbinafine Hcl	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	12
Prednisone	Prednisone	22	suppressed
Atazanavir Sulfate	Atazanavir Sulfate	21	suppressed
Ozempic	Semaglutide	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	suppressed
Clonazepam	Clonazepam	20	suppressed
Methadone Hcl	Methadone Hcl	20	suppressed
Nevirapine	Nevirapine	20	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Rybelsus	Semaglutide	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Furosemide	Furosemide	18	suppressed
Juluca	Dolutegravir/Rilpivirine	18	suppressed
Lamivudine	Lamivudine	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Lidocaine	Lidocaine	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	suppressed
Latanoprost	Latanoprost	16	suppressed
Metoprolol Succinate	Metoprolol Succinate	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Maraviroc	Maraviroc	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	12	suppressed
Novolin N	Insulin Nph Human Isophane	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	12	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	12	suppressed
Zidovudine	Zidovudine	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Imiquimod	Imiquimod	11	suppressed
Lopinavir-Ritonavir	Lopinavir/Ritonavir	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error